{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:45:43Z","timestamp":1779893143443,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.leukres.2024.107569","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:54:12Z","timestamp":1724349252000},"page":"107569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Decitabine consolidation after CD19\/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed\/refractory B-ALL patients"],"prefix":"10.1016","volume":"145","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunju","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2024.107569_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2024.107569_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2024.107569_bib3","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib4","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107569_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-019-0741-6","article-title":"Haploidentical CD19\/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Jia","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107569_bib7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.leukres.2024.107569_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-023-00819-5","article-title":"Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy?","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107569_bib12","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood-2002-08-2466","article-title":"Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia","volume":"101","author":"Shen","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107569_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00432-015-2063-6","article-title":"Hypermethylation of p15 gene associated with an inferior poor long-term outcome in childhood acute lymphoblastic leukemia","volume":"142","author":"Mai","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107569_bib14","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1172\/JCI66203","article-title":"Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia","volume":"123","author":"Figueroa","year":"2013","journal-title":"J. Clin. Investigtig."},{"issue":"3","key":"10.1016\/j.leukres.2024.107569_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4161\/epi.27585","article-title":"Epigenetic deregulation in pediatric acute lymphoblastic leukemia","volume":"9","author":"Chatterton","year":"2014","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.leukres.2024.107569_bib16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13050","article-title":"Safety and clinical activity of 5-aza-2\u2032-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed\/refractory acute lymphocytic leukaemia","volume":"167","author":"Benton","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41409-023-01948-y","article-title":"Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia","volume":"58","author":"Fan","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107569_bib18","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","article-title":"Epigenetic strategies to boost CAR T cell therapy","volume":"29","author":"Akbari","year":"2021","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cac2.12313","article-title":"Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials","volume":"42","author":"Xu","year":"2022","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40164-023-00397-z","article-title":"Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19\/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed\/refractory B-ALL patients","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2024.107569_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2024.107569_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.leukres.2024.107569_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2024.107569_bib25","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2024.107569_bib26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II Trial","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107569_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.leukres.2024.107569_bib28","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"9","key":"10.1016\/j.leukres.2024.107569_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep."},{"issue":"620","key":"10.1016\/j.leukres.2024.107569_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2024.107569_bib32","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107569_bib33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","article-title":"TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children","volume":"36","author":"Qian","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107569_bib34","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children","volume":"34","author":"Pan","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","article-title":"Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.leukres.2024.107569_bib36","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3324\/haematol.2021.280153","article-title":"Decitabine salvage for TP53 -mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","volume":"107","author":"Ferraro","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2024.107569_bib37","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41409-021-01230-z","article-title":"Decitabine may improve CAR-T efficacy in refractory\/relapsed acute leukemia patients carrying TP53 alterations","volume":"56","author":"Qu","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"15","key":"10.1016\/j.leukres.2024.107569_bib38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107569_bib39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigen receptor T-cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:53:39Z","timestamp":1726232019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"alternative-id":["S0145212624001358"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107569","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decitabine consolidation after CD19\/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed\/refractory B-ALL patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107569"}}